Health Care & Life Sciences » Pharmaceuticals | Bellerophon Therapeutics Inc.

Bellerophon Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
429.00
388.00
377.00
400.00
373.00
362
Gross Income
429.00
388.00
377.00
400.00
373.00
362
SG&A Expense
61,569.00
59,365.00
46,484.00
23,709.00
24,226.00
27,518
EBIT
61,998.00
59,753.00
46,861.00
-
24,599.00
27,880
Unusual Expense
-
-
1,374.00
238.00
30,403.00
24,877
Non Operating Income/Expense
-
-
1,667.00
-
-
-
Pretax Income
61,998.00
59,674.00
46,459.00
24,252.00
54,818.00
2,625
Income Tax
-
-
-
438.00
-
5,439
Consolidated Net Income
61,998.00
59,674.00
46,459.00
23,814.00
54,818.00
2,814
Net Income
61,998.00
59,674.00
46,459.00
23,814.00
54,818.00
2,814
Net Income After Extraordinaries
61,998.00
59,674.00
46,459.00
23,814.00
54,818.00
2,814
Net Income Available to Common
61,998.00
59,674.00
46,459.00
23,814.00
54,818.00
2,814
EPS (Basic)
4.54
4.37
3.79
1.58
1.41
0.04
Basic Shares Outstanding
13,655.30
13,655.30
12,267.70
15,057.60
38,950.90
57,446.50
EPS (Diluted)
4.54
4.37
3.79
1.58
1.41
0.04
Diluted Shares Outstanding
13,655.30
13,655.30
12,267.70
15,057.60
38,950.90
65,048.90
EBITDA
61,569.00
59,365.00
46,484.00
23,709.00
24,226.00
27,518
Non-Operating Interest Income
-
79.00
109.00
95.00
184.00
378

About Bellerophon Therapeutics

View Profile
Address
184 Liberty Corner Road
Warren New Jersey 07059
United States
Employees -
Website http://www.bellerophon.com
Updated 07/08/2019
Bellerophon Therapeutics, Inc clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.